Engineering and Development

Management and Executive

Chairman and CEO

EVP, Chief Commercial Officer

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Vor Biopharma files for 1-for-20 reverse stock split - SEC filing

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Senior Director, Field Medical Lead-West

Vor BioPharma is dedicated to transforming autoimmune disease treatment through innovative therapies. They are seeking a Senior Director, Field Medical Lead to establish the company as a scientific leader in the US, focusing on neurology and rheumatology while mentoring a team of MSLs and engaging with external experts.

Chief People Officer

Sign up with Google

Sign in with Google